BR112023021225A2 - Anticorpos anti-cd20 e estruturas t car - Google Patents
Anticorpos anti-cd20 e estruturas t carInfo
- Publication number
- BR112023021225A2 BR112023021225A2 BR112023021225A BR112023021225A BR112023021225A2 BR 112023021225 A2 BR112023021225 A2 BR 112023021225A2 BR 112023021225 A BR112023021225 A BR 112023021225A BR 112023021225 A BR112023021225 A BR 112023021225A BR 112023021225 A2 BR112023021225 A2 BR 112023021225A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- structures
- car
- tcar
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464424—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/11—Antigen recognition domain
- A61K2239/13—Antibody-based
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
anticorpos anti-cd20 e estruturas t car. são divulgados anticorpos (por exemplo, uniabstm) e estruturas t car anti-cd20, junto com métodos de produção de tais anticorpos e estruturas t car, composições, incluindo composições farmacêuticas, compreendendo tais anticorpos e estruturas t car, e seu uso para tratar distúrbios que são caracterizados pela expressão de cd20.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163176161P | 2021-04-16 | 2021-04-16 | |
PCT/US2022/025077 WO2022221698A1 (en) | 2021-04-16 | 2022-04-15 | Anti-cd20 antibodies and car-t structures |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023021225A2 true BR112023021225A2 (pt) | 2023-12-19 |
Family
ID=81585457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023021225A BR112023021225A2 (pt) | 2021-04-16 | 2022-04-15 | Anticorpos anti-cd20 e estruturas t car |
Country Status (12)
Country | Link |
---|---|
US (1) | US20240117063A1 (pt) |
EP (1) | EP4323403A1 (pt) |
JP (1) | JP2024513951A (pt) |
KR (1) | KR20230171952A (pt) |
CN (1) | CN117337303A (pt) |
AU (1) | AU2022259688A1 (pt) |
BR (1) | BR112023021225A2 (pt) |
CA (1) | CA3215241A1 (pt) |
CO (1) | CO2023013543A2 (pt) |
CR (1) | CR20230525A (pt) |
IL (1) | IL306045A (pt) |
WO (1) | WO2022221698A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202005880XA (en) | 2017-12-22 | 2020-07-29 | Teneobio Inc | Heavy chain antibodies binding to cd22 |
JP2022537931A (ja) | 2019-06-14 | 2022-08-31 | テネオバイオ, インコーポレイテッド | Cd22及びcd3に結合する多重特異性重鎖抗体 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
DE69731289D1 (de) | 1996-03-18 | 2004-11-25 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
US7608429B2 (en) | 2002-10-31 | 2009-10-27 | Genentech, Inc. | Methods and compositions for increasing antibody production |
CA2513113A1 (en) | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
EP1864998B2 (en) | 2004-07-22 | 2022-06-22 | Erasmus University Medical Center Rotterdam | Binding molecules |
US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
CN104877026B (zh) | 2009-03-10 | 2019-10-25 | 比奥根Ma公司 | 抗-bcma抗体 |
GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
AU2017281034B2 (en) | 2016-06-21 | 2024-03-14 | Teneobio, Inc. | CD3 binding antibodies |
KR20190052006A (ko) | 2016-08-24 | 2019-05-15 | 테네오바이오, 인코포레이티드 | 변형된 중쇄-단독 항체를 생산하는 형질전환 비-인간 동물 |
US10246514B2 (en) * | 2016-09-12 | 2019-04-02 | The United States Of America, As Represented By The Secretary Of The Navy | Single domain antibodies that bind to human CD20 |
WO2018052503A1 (en) | 2016-09-14 | 2018-03-22 | Teneobio, Inc. | Cd3 binding antibodies |
WO2019126724A1 (en) * | 2017-12-22 | 2019-06-27 | Bluebird Bio, Inc. | Multivalent chimeric antigen receptor |
JOP20210253A1 (ar) * | 2019-04-05 | 2023-01-30 | Teneobio Inc | أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ psma |
-
2022
- 2022-04-15 CN CN202280027742.6A patent/CN117337303A/zh active Pending
- 2022-04-15 EP EP22721975.5A patent/EP4323403A1/en active Pending
- 2022-04-15 JP JP2023562540A patent/JP2024513951A/ja active Pending
- 2022-04-15 KR KR1020237038039A patent/KR20230171952A/ko unknown
- 2022-04-15 AU AU2022259688A patent/AU2022259688A1/en active Pending
- 2022-04-15 CR CR20230525A patent/CR20230525A/es unknown
- 2022-04-15 IL IL306045A patent/IL306045A/en unknown
- 2022-04-15 BR BR112023021225A patent/BR112023021225A2/pt unknown
- 2022-04-15 WO PCT/US2022/025077 patent/WO2022221698A1/en active Application Filing
- 2022-04-15 CA CA3215241A patent/CA3215241A1/en active Pending
-
2023
- 2023-09-25 US US18/473,965 patent/US20240117063A1/en active Pending
- 2023-10-13 CO CONC2023/0013543A patent/CO2023013543A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP4323403A1 (en) | 2024-02-21 |
CR20230525A (es) | 2024-02-19 |
US20240117063A1 (en) | 2024-04-11 |
AU2022259688A1 (en) | 2023-10-05 |
JP2024513951A (ja) | 2024-03-27 |
IL306045A (en) | 2023-11-01 |
CN117337303A (zh) | 2024-01-02 |
WO2022221698A1 (en) | 2022-10-20 |
CO2023013543A2 (es) | 2023-10-30 |
CA3215241A1 (en) | 2022-10-20 |
KR20230171952A (ko) | 2023-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112023021225A2 (pt) | Anticorpos anti-cd20 e estruturas t car | |
BR112019012354A2 (pt) | anticorpos apenas de cadeia pesada anti-bcma | |
CL2019003627A1 (es) | Anticuerpos anti-pd-1 y sus usos. (solicitud divisional 201900628) | |
AR111288A1 (es) | Anticuerpos anti-phf-tau y sus usos | |
BR112021020629A2 (pt) | Compostos bicíclicos | |
BR112021022576A2 (pt) | Inibidores de autofagia de heteroarilaminopirimidina amida e métodos de uso dos mesmos | |
BR112019017329A2 (pt) | imunoconjugados, um ou mais polinucleotídeos e vetores, métodos para a produção de um imunoconjugado, tratamento de uma doença e para a estimulação do sistema imunológico, composição, uso do imunoconjugado, invenção e usos da composição | |
UY38476A (es) | Inhibidores de arg1 y/o arg2 | |
DOP2022000077A (es) | Aminas bicíclicas como inhibidoras de la cdk2 | |
CL2019001740A1 (es) | Novedoso conjugado de amanitina. | |
CO2023015484A2 (es) | Compuesto, composiciones y métodos para el tratamiento de trastornos | |
BR112017019978A2 (pt) | anticorpo ou um fragmento de ligação com antígeno, conjugado, receptor de antígeno, cadeia, conjugado de cadeia, proteína de fusão, célula t, polinucleotídeo, vetor, célula ex vivo, método para produzir uma cadeia, método para produzir um anticorpo, composição farmacêutica, método para tratamento de câncer, glicopeptídeo, método para gerar um anticorpo | |
BR112021024956A2 (pt) | Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3 | |
BRPI0821110B8 (pt) | anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo | |
CO2020012060A2 (es) | Inhibidores de la arginasa | |
CL2021002503A1 (es) | Anticuerpos contra triptasa, composiciones de estos y usos de estos. (divisional de solicitud 201902251) | |
BR112019017403A2 (pt) | composições e métodos para o tratamento de câncer | |
BR112023020450A2 (pt) | Anticorpos anti-cd19 e estruturas car-t | |
BR112018072768A2 (pt) | suspensão, composição farmacêutica, método para formar uma suspensão fulvestrant aquosa, suspensão fulvestrant aquosa e método para tratar um indivíduo tendo câncer de mama | |
BR112022021690A2 (pt) | Anticorpos de cadeia pesada multispecíficos com regiões constantes de cadeia pesada modificadas | |
CO2021009129A2 (es) | Tubulisinas y conjugados de proteína-tubulisina | |
BR112021025544A2 (pt) | Inibidores de autofagia de aminopirimidina amida e métodos de uso dos mesmos | |
BR112022027101A2 (pt) | Anticorpos multiespecíficos que se ligam a bcma | |
MX2022012628A (es) | Anticuerpos anti-phf-tau y usos de estos. | |
MX2023004869A (es) | Anticuerpos contra sars-cov-2 y usos de los mismos. |